HCSGD entry for SERPINA5

1. General information

Official gene symbolSERPINA5
Entrez ID5104
Gene full nameserpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5
Other gene symbolsPAI-3 PAI3 PCI PCI-B PLANH3 PROCI
Links to Entrez GeneLinks to Entrez Gene

2. Neighbors in the network

color bar
This gene isn't in Literature mining network.

3. Gene ontology annotation

GO ID

GO term

Evidence

Category

GO:0001972Retinoic acid bindingIDAmolecular_function
GO:0002020Protease bindingIPImolecular_function
GO:0002080Acrosomal membraneIDAcellular_component
GO:0004867Serine-type endopeptidase inhibitor activityIDA IEAmolecular_function
GO:0005539Glycosaminoglycan bindingTASmolecular_function
GO:0005576Extracellular regionIBA NAS TAScellular_component
GO:0005615Extracellular spaceIDA IEAcellular_component
GO:0006869Lipid transportIEAbiological_process
GO:0007283SpermatogenesisIEA ISSbiological_process
GO:0007342Fusion of sperm to egg plasma membraneNASbiological_process
GO:0008201Heparin bindingTASmolecular_function
GO:0009897External side of plasma membraneIDAcellular_component
GO:0010951Negative regulation of endopeptidase activityIBAbiological_process
GO:0016020MembraneIDAcellular_component
GO:0030162Regulation of proteolysisIBAbiological_process
GO:0031091Platelet alpha granuleIDAcellular_component
GO:0031094Platelet dense tubular networkIDAcellular_component
GO:0031210Phosphatidylcholine bindingIDAmolecular_function
GO:0032190Acrosin bindingIPImolecular_function
GO:0036024Protein C inhibitor-TMPRSS7 complexIDAcellular_component
GO:0036025Protein C inhibitor-TMPRSS11E complexIDAcellular_component
GO:0036026Protein C inhibitor-PLAT complexIDAcellular_component
GO:0036027Protein C inhibitor-PLAU complexIDAcellular_component
GO:0036028Protein C inhibitor-thrombin complexIDAcellular_component
GO:0036029Protein C inhibitor-KLK3 complexIDAcellular_component
GO:0036030Protein C inhibitor-plasma kallikrein complexIDAcellular_component
GO:0043234Protein complexIDAcellular_component
GO:0045861Negative regulation of proteolysisIEAbiological_process
GO:0070062Extracellular vesicular exosomeIDAcellular_component
GO:0097181Protein C inhibitor-coagulation factor V complexIDAcellular_component
GO:0097182Protein C inhibitor-coagulation factor Xa complexIDAcellular_component
GO:0097183Protein C inhibitor-coagulation factor XI complexIDAcellular_component
Entries Per Page
Displaying Page of

4. Expression levels in datasets

  • Meta-analysis result

p-value upp-value downFDR upFDR down
0.34007785420.91589349950.99999024731.0000000000

  • Individual experiment result
    ( "-" represent NA in the specific microarray platform )

Data sourceUp or downLog fold change
GSE11954Up0.0590199824
GSE13712_SHEARUp0.0879756340
GSE13712_STATICUp0.2902934715
GSE19018Up0.2289043408
GSE19899_A1Down-0.0721375947
GSE19899_A2Up0.0706852060
PubMed_21979375_A1Down-0.0445132628
PubMed_21979375_A2Up0.1105559384
GSE35957Down-0.0508648553
GSE36640Up0.2431162762
GSE54402Down-0.0613444373
GSE9593Down-0.3220974338
GSE43922Up0.0157653252
GSE24585Up0.3067244560
GSE37065Down-0.0555976896
GSE28863_A1Down-0.0173949385
GSE28863_A2Up0.5302234183
GSE28863_A3Up0.2631045919
GSE28863_A4Up0.0091451882
GSE48662Down-0.0894489355

5. Regulation relationships with compounds/drugs/microRNAs

  • Compounds

Not regulated by compounds

  • Drugs

Name

Drug

Accession number

UrokinaseDB00013 BTD00030 | BIOD00030
T-1249DB05413 -

  • MicroRNAs

  • mirTarBase
No target information from mirTarBase
  • mirRecord
No target information from mirRecord

6. Text-mining results about the gene

Gene occurances in abstracts of cellular senescence-associated articles: 2 abstracts the gene occurs.


PubMed ID of the article

Sentenece the gene occurs

25874702Angiographic late in-stent loss after percutaneous coronary intervention (PCI) was evaluated at a six-month follow-up
25874702CONCLUSIONS: Microalbuminuria in AMI patients is closely associated with functional disorder of EPCs via cellular senescence, that predicts the aggravation of coronary remodeling after PCI
23070029Indeed, recent clinical trials with ticagrelor (DISPERSE, DISPERSE-II, and PLATO), and elinogrel (INNOVATE PCI) revealed double-digit rates of dyspnea after novel reversible antiplatelet agents
Entries Per Page
Displaying Page of